US-based biotechnology company Atreca has secured $35m in a series B financing round led by Wellington Management Company.

The funds will be utilised to progress the development of the company’s antibody-based therapeutics.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Calithera Biosciences has announced a public offering of common stock shares to raise up to $50m.

The US-based clinical-stage pharmaceutical company plans to use the funds towards general corporate purposes.

Spring Bank Pharmaceuticals plans to raise up to $50m through a public offering of shares of its common stock.

"Spring Bank Pharmaceuticals plans to raise up to $50m through a public offering of shares of its common stock."

US-based clinical-stage biopharmaceutical company Spring Bank plans to use the proceeds for general corporate purposes.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Coherus BioSciences (formerly known as BioGenerics) has announced the private placement of six million shares of its common stock priced at $11.44 a share to raise $75m.

The company intends to raise a total of $150m in two tranches, with $75m to be raised in the first tranche.

The US-based biopharmaceutical company plans to use the funds towards the development of its pegfilgrastim biosimilar product candidate CHS-1701, as well as general corporate purposes.

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact.

Excellence in Action
Recognised with 2025 Excellence Awards for Research and Development and Marketing , Novotech converted FDA/EMA fast track designations into faster HDV trial timelines while translating complex HBV science into sponsor ready insights. Discover how this dual strength in execution and communication is reshaping liver disease clinical development.

Discover the Impact